Supira Medical, a Los Gatos, CA-based Shifamed portfolio company focused on developing a next-generation solution for temporary mechanical circulatory support, raised $30M in Series C funding.
The round was led by Cormorant Asset Management and The Capital Partnership, with participation from 415 CAPITAL, AMED Ventures, and PA MedTech VC Fund.
The company intends to use the funds to finalize product development and initiate a first-in-human clinical study for its percutaneous ventricular assist device.
Led by CEO Dr. Nitin Salunke, Supira Medical is focused on development of a next generation percutaneous ventricular assist device (pVAD) for use in high-risk patients undergoing interventional procedures. Percutaneous ventricular assist devices (pVADs) are used during stent placement or angioplasty to provide temporary mechanical support for high-risk patients with severe coronary artery disease or comorbidities. Additionally, pVADs are used to treat patients suffering from cardiogenic shock (CS), a condition that can occur following a severe heart attack, and is associated with a high rate of morbidity as a patient’s heart is suddenly too weak to adequately pump blood to vital organs.
FinSMEs
28/02/2022